Find Fidaxomicin manufacturers, exporters & distributors on PharmaCompass

Fidaxomicin

Fidaxomicin

Contact Supplier

Aurigene is a global leader in accelerating drug innovation through discovery, development & manufacturing.

Contact Supplier

Midas Pharma provides expertise in developing and supplying APIs, finished products, and intermediates.

Contact Supplier

ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

Contact Supplier

Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

Contact Supplier

xyz-pharma-m-2025-01-06

Contact Supplier

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

17 API Suppliers, 3 USDMF, 1 EU WC, 5 NDC API, 13 Listed Suppliers

17 API Suppliers
3 USDMF
1 EU WC
5 NDC API
13 Listed Suppliers

DEVELOPMENTS

4 Drugs in Development

4 Drugs in Development

FINISHED DOSAGE FORMULATIONS

9 FDF Dossiers, 3 FDA Orange Book, 4 Europe, 1 Canada, 1 South Africa

9 FDF Dossiers
3 FDA Orange Book
4 Europe
1 Canada
1 South Africa

RELATED EXCIPIENT COMPANIES

4 SPI Pharma, 2 Seqens, 2 DKSH, 2 Faran Shimi Pharmaceutical, 10 Gangwal Healthcare, 1 Nanjing Well Pharmaceutical, 3 Actylis, 1 Aeon Procare, 4 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 9 BASF, 5 Corel Pharma Chem, 3 DFE Pharma, 1 Finar, 6 Gangwal Chemicals, 3 Ideal Cures Pvt Ltd, 3 Ingredion Pharma Solutions, 7 Kerry, 7 Microlex e.U, 2 Nomisma Healthcare, 1 Novo Excipients, 2 Pharmatrans-Sanaq, 2 Pluviaendo, 3 Prachin Chemical, 17 Roquette, 1 Seppic, 3 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 10 Sigachi Industries, 3 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

34 Fillers, Diluents & Binders, 21 Coating Systems & Additives, 20 Direct Compression, 19 Disintegrants & Superdisintegrants, 16 Thickeners and Stabilizers, 14 Controlled & Modified Release, 13 Lubricants & Glidants, 11 Co-Processed Excipients, 8 Granulation, 8 Topical, 6 Taste Masking, 5 Chewable & Orodispersible Aids, 5 Solubilizers, 4 Parenteral, 4 Film Formers & Plasticizers, 2 Coloring Agents, 2 Emulsifying Agents, 1 API Stability Enhancers, 1 Rheology Modifiers

DIGITAL CONTENT

5 NEWS #PharmaBuzz

media
5 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

1 US Medicaid Prescriptions, 4 Finished Drug Prices, 4 Annual Reports

globalSalesInformation
1 US Medicaid Prescriptions
4 Finished Drug Prices
4 Annual Reports

MARKET PLACE

9 APIs, 1 FDF Dossiers

marketPlace
9 APIs
1 FDF Dossiers

PATENTS & EXCLUSIVITIES

22 US Patents, 2 US Exclusivities, 5 Health Canada Patents

patents
22 US Patents
2 US Exclusivities
5 Health Canada Patents

Fidaxomicin

Synopsis

ACTIVE PHARMA INGREDIENTS

17

API Suppliers

3

USDMF

0

CEP/COS

CEP/COS Certifications

0

JDMF

1

EU WC

0

KDMF

5

NDC API

0

VMF

13

Listed Suppliers

API REF. PRICE (USD/KG)

$

$ 0

MARKET PLACE

9

API

1

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

9

FDF Dossiers

3

FDA Orange Book

FDA (Orange Book)

4

Europe

1

Canada

0

Australia

1

South Africa

0

Listed Dossiers

4DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

22

US Patents

2

US Exclusivities

5

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

5

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

103,081,747

Annual Reports (USD Million)

585

Finished Drug Prices

117 RELATED EXCIPIENT COMPANIES

194EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Click the button for full data set

Also known as: Tiacumicin b, Dificid, Dificlir, Lipiarmycin, Opt-80, 873857-62-6

Molecular Formula

C₅₂H₇₄Cl₂O₁₈

Molecular Weight

1058.0 g/mol

InChI Key

ZVGNESXIJDCBKN-UUEYKCAUSA-N

FDA UNII

Z5N076G8YQ

Fidaxomicin

A narrow-spectrum macrolide antibacterial agent that is used in the treatment of diarrhea associated with CLOSTRIDIUM DIFFICILE INFECTION.

Fidaxomicin is a Macrolide Antibacterial.

1 2D Structure

Fidaxomicin

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

[(2R,3S,4S,5S,6R)-6-[[(3E,5E,8S,9E,11S,12R,13E,15E,18S)-12-[(2R,3S,4R,5S)-3,4-dihydroxy-6,6-dimethyl-5-(2-methylpropanoyloxy)oxan-2-yl]oxy-11-ethyl-8-hydroxy-18-[(1R)-1-hydroxyethyl]-9,13,15-trimethyl-2-oxo-1-oxacyclooctadeca-3,5,9,13,15-pentaen-3-yl]methoxy]-4-hydroxy-5-methoxy-2-methyloxan-3-yl] 3,5-dichloro-2-ethyl-4,6-dihydroxybenzoate

2.1.2 InChI

InChI=1S/C52H74Cl2O18/c1-13-30-22-26(6)33(56)18-16-15-17-31(23-66-51-45(65-12)42(61)44(29(9)67-51)69-49(64)35-32(14-2)36(53)39(58)37(54)38(35)57)48(63)68-34(28(8)55)20-19-25(5)21-27(7)43(30)70-50-41(60)40(59)46(52(10,11)72-50)71-47(62)24(3)4/h15-17,19,21-22,24,28-30,33-34,40-46,50-51,55-61H,13-14,18,20,23H2,1-12H3/b16-15+,25-19+,26-22+,27-21+,31-17+/t28-,29-,30+,33+,34+,40-,41+,42+,43+,44-,45+,46+,50-,51-/m1/s1

2.1.3 InChI Key

ZVGNESXIJDCBKN-UUEYKCAUSA-N

2.1.4 Canonical SMILES

CCC1C=C(C(CC=CC=C(C(=O)OC(CC=C(C=C(C1OC2C(C(C(C(O2)(C)C)OC(=O)C(C)C)O)O)C)C)C(C)O)COC3C(C(C(C(O3)C)OC(=O)C4=C(C(=C(C(=C4O)Cl)O)Cl)CC)O)OC)O)C

2.1.5 Isomeric SMILES

CC[C@H]1/C=C(/[C@H](C/C=C/C=C(/C(=O)O[C@@H](C/C=C(/C=C(/[C@@H]1O[C@H]2[C@H]([C@H]([C@@H](C(O2)(C)C)OC(=O)C(C)C)O)O)\C)\C)[C@@H](C)O)\CO[C@H]3[C@H]([C@H]([C@@H]([C@H](O3)C)OC(=O)C4=C(C(=C(C(=C4O)Cl)O)Cl)CC)O)OC)O)\C

2.2 Other Identifiers

2.2.1 UNII

Z5N076G8YQ

2.3 Synonyms

2.3.1 MeSH Synonyms

1. Dificid

2. Lipiarmycin

3. Lipiarmycin A3

4. Lipiarmycin A4

5. Lipiarmycin B

6. Lipiarmycin B3

7. Lipiarmycin B4

8. Par 101

9. Par-101

10. Par101

11. Tiacumicin B

12. Tiacumicin C

2.3.2 Depositor-Supplied Synonyms

1. Tiacumicin B

2. Dificid

3. Dificlir

4. Lipiarmycin

5. Opt-80

6. 873857-62-6

7. Par-101

8. Clostomicin B1

9. Lipiarmicin

10. Difimicin

11. Z5n076g8yq

12. Lipiarmycin A3

13. R-tiacumicin B

14. Lipiarmycin A 3

15. Fidaxomicin [usan]

16. Fidaxomicin [usan:inn]

17. Unii-z5n076g8yq

18. Lipiarrmycin

19. Par 01

20. Clostomycin B1

21. Fidaxomicin (dificid)

22. Brn 5228707

23. Fidaxomicin [mi]

24. Fidaxomicin [inn]

25. Fidaxomicin [jan]

26. Fidaxomicin [vandf]

27. Fidaxomicin [who-dd]

28. Chembl1255800

29. Schembl10000818

30. Fidaxomicin, >=98% (hplc)

31. Gtpl10909

32. Fidaxomicin [orange Book]

33. Dtxsid901016415

34. Fi8

35. Mfcd27976367

36. Db08874

37. F1216

38. Opt-80;par-101;clostomicin B1;tiacumicin B

39. Q5446672

40. (2r,3s,4s,5s,6r)-6-{[(3e,5e,8s,9e,11s,12r,13e,15e,18s)-12-{[(2r,3s,4r,5s)-3,4-dihydroxy-6,6-dimethyl-5-[(2-methylpropanoyl)oxy]oxan-2-yl]oxy}-11-ethyl-8-hydroxy-18-[(1r)-1-hydroxyethyl]-9,13,15-trimethyl-2-oxo-1-oxacyclooctadeca-3,5,9,13,15-pentaen-3-yl]methoxy}-4-hydroxy-5-methoxy-2-methyloxan-3-yl 3,5-dichloro-2-ethyl-4,6-dihydroxybenzoate

41. [(2r,3s,4s,5s,6r)-6-[[(3e,5e,8s,9e,11s,12r,13e,15e,18s)-12-[(2r,3s,4r,5s)-3,4-dihydroxy-6,6-dimethyl-5-(2-methylpropanoyloxy)oxan-2-yl]oxy-11-ethyl-8-hydroxy-18-[(1r)-1-hydroxyethyl]-9,13,15-trimethyl-2-oxo-1-oxacyclooctadeca-3,5,9,13,15-pentaen-3-yl]methoxy]-4-hydroxy-5-methoxy-2-methyloxan-3-yl] 3,5-dichloro-2-ethyl-4,6-dihydroxybenzoate

2.4 Create Date

2006-10-25

3 Chemical and Physical Properties

Molecular Formula	C₅₂H₇₄Cl₂O₁₈
Molecular Weight	1058.0 g/mol
XLogP3	6.4
Hydrogen Bond Donor Count	7
Hydrogen Bond Acceptor Count	18
Rotatable Bond Count	15
Exact Mass	1056.4252209 g/mol
Monoisotopic Mass	1056.4252209 g/mol
Topological Polar Surface Area	267 Å²
Heavy Atom Count	72
Formal Charge	0
Complexity	1970
Isotope Atom Count	0
Defined Atom Stereocenter Count	14
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	5
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Drug and Medication Information

4.1 Drug Information

1 of 2
Drug Name	Dificid
PubMed Health	Fidaxomicin (By mouth)
Drug Classes	Antibiotic
Drug Label	DIFICID (fidaxomicin) is a macrolide antibacterial drug for oral administration. Its CAS chemical name is Oxacyclooctadeca-3,5,9,13,15-pentaen-2-one, 3-[[[6-deoxy-4-O-(3,5-dichloro-2-ethyl-4,6-dihydroxybenzoyl)-2-O-methyl--D-mannopyranosyl]oxy]meth...
Active Ingredient	Fidaxomicin
Dosage Form	Tablet
Route	Oral
Strength	200mg
Market Status	Prescription
Company	Cubist Pharms

2 of 2
Drug Name	Dificid
PubMed Health	Fidaxomicin (By mouth)
Drug Classes	Antibiotic
Drug Label	DIFICID (fidaxomicin) is a macrolide antibacterial drug for oral administration. Its CAS chemical name is Oxacyclooctadeca-3,5,9,13,15-pentaen-2-one, 3-[[[6-deoxy-4-O-(3,5-dichloro-2-ethyl-4,6-dihydroxybenzoyl)-2-O-methyl--D-mannopyranosyl]oxy]meth...
Active Ingredient	Fidaxomicin
Dosage Form	Tablet
Route	Oral
Strength	200mg
Market Status	Prescription
Company	Cubist Pharms

4.2 Drug Indication

Fidaxomicin is indicated for the treatment of _Clostridioides_ (formerly _Clostridium_) _difficile_-associated diarrhea in adult and pediatric patients 6 months of age and older. Fidaxomicin should only be used in patients with proven or strongly suspected _C. difficile_ infection to reduce the risk of development of drug-resistant bacteria and maximize the therapeutic effectiveness of fidaxomicin and other antimicrobial agents.

FDA Label

Dificlir film-coated tablets is indicated for the treatment of Clostridioides difficile infections (CDI) also known as C. difficile-associated diarrhoea (CDAD) in adult and paediatric patients with a body weight of at least 12. 5 kg.

Consideration should be given to official guidelines on the appropriate use of antibacterial agents.

Dificlir granules for oral suspension is indicated for the treatment of Clostridioides difficile infections (CDI) also known as C. difficile-associated diarrhoea (CDAD) in adults and paediatric patients from birth to < 18 years of age.

Consideration should be given to official guidelines on the appropriate use of antibacterial agents.

5 Pharmacology and Biochemistry

5.1 Pharmacology

Fidaxomicin has a narrow-spectrum antibacterial profile, with potent bactericidal activity specifically against C. difficile. The minimum inhibitory concentration for 90% of organisms for fidaxomicin against _C. difficile_ ranged from 0.0078 to 2 g/mL _in vitro_. The bactericidal activity of fidaxomicin is time-dependent. Other than _C. difficile_, fidaxomicin has moderate inhibitory activity against Gram-positive bacteria (_S. aureus_ and _Enterococcus spp._) and poor activity against normal colonic flora, including anaerobes and enteric Gram-negative bacilli. Isolates of _C. difficile_ that are resistant to rifamycins or other antimicrobial classes (such as cephalosporins, fluoroquinolones, clindamycin) were not shown to be cross-resistant to fidaxomicin.

5.2 MeSH Pharmacological Classification

Anti-Bacterial Agents

Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)

5.3 FDA Pharmacological Classification

5.3.1 Active Moiety

FIDAXOMICIN

5.3.2 FDA UNII

Z5N076G8YQ

5.3.3 Pharmacological Classes

Macrolides [CS]; Macrolide Antibacterial [EPC]

5.4 ATC Code

A07AA12

A - Alimentary tract and metabolism

A07 - Antidiarrheals, intestinal antiinflammatory/antiinfective agents

A07A - Intestinal antiinfectives

A07AA - Antibiotics

A07AA12 - Fidaxomicin

5.5 Absorption, Distribution and Excretion

Absorption

Following oral administration of a single dose of 200 mg fidaxomicin in healthy adults, the C_max of fidaxomicin and its main metabolite OP-1118 were 5.20 2.81 ng/mL and 12.0 6.06, respectively. The median T_max of fidaxomicin was 2 hours. The systemic absorption of fidaxomicin following oral administration is minimal. In a food-effect study involving healthy adults in either with a high-fat meal versus under fasting conditions, the C_max of fidaxomicin and OP-1118 were decreased by 21.5% and 33.4%, respectively; however, this effect is deemed to be clinically insignificant as the therapeutic action of fidaxomicin does not depend on drug concentrations in the systemic circulation.

Route of Elimination

Following oral administration, fidaxomicin is mainly excreted in feces. More than 92% of the dose was recovered in the faces as either the unchanged parent drug or metabolites in one study consisting of healthy adults receiving single doses of 200 mg and 300 mg of fidaxomicin. In another study of healthy adults, approximately 0.59% fo the oral dose (200 mg) administered was recovered in the urine as the main metabolite, OP-1118.

Volume of Distribution

Fidaxomicin is mainly confined to the gastrointestinal tract when orally administered. There is limited information on the volume of distribution of fidaxomicin.

Clearance

There is limited information on the clearance of fidaxomicin.

5.6 Metabolism/Metabolites

Following oral administration, fidaxomicin is transformed to its main and pharmacologically active metabolite, OP-1118, via hydrolysis at the isobutyryl ester. As cytochrome enzymes are not involved in the metabolism of fidaxomicin, it is speculated that this biotransformation is mediated by gastric acid or enzymatic activity of intestinal microsomes.

5.7 Biological Half-Life

Following oral administration of a single dose of 200 mg fidaxomicin in healthy adults, the elimination half-life of fidaxomicin was approximately 11.7 4.80 hours.

5.8 Mechanism of Action

_Clostridium difficile_ is a Gram-positive bacterium that causes various gastrointestinal complications, such as antibiotic-associated diarrhea. _C. difficile_ infection can be caused by antibiotic therapy, resulting in the disruption of the human gut flora leads to an overgrowth of _C. difficile_. The consequences of _C. difficile_ infection can be mild to severe and sometimes fatal. Fidaxomicin gets hydrolyzed to its active metabolite, OP-1118, upon oral administration. Both compounds mediate a bactericidal activity against _C. difficile_ by inhibiting bacterial RNA polymerase at the initiation phase of the transcription cycle. The RNA polymerase is an essential bacterial enzyme that regulates gene expression, catalyzes nucleic acid interactions, and promotes several bacterial enzymatic reactions critical for bacterial survival. The core RNA polymerase is composed of a complex of different subunits and contains the active site. To initiate bacterial transcription, the active site of the core RNA polymerase binds to a promoter-specificity initiation factor, which locates and binds to a promoter region of the DNA. The DNA-RNA polymerase interaction promotes subsequent steps of transcription, which involves the separation of DNA strands. Fidaxomicin binds to the DNA template-RNA polymerase complex, thereby preventing the initial separation of DNA strands during transcription and inhibiting messenger RNA synthesis. The narrow spectrum of antimicrobial activity of fidaxomicin may be explained by the unique target site of fidaxomicin and differing subunits of the core structure of RNA polymerase among bacterial species.

API SUPPLIERS

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

EU WC

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drugs in Development

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDF Dossiers

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDA Orange Book

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Europe

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Canada

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

South Africa

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Fillers, Diluents & Binders

Coating Systems & Additives

Direct Compression

Disintegrants & Superdisintegrants

Thickeners and Stabilizers

Controlled & Modified Release

Lubricants & Glidants

Co-Processed Excipients

Granulation

Topical

Taste Masking

Chewable & Orodispersible Aids

Solubilizers

Parenteral

Film Formers & Plasticizers

Coloring Agents

Emulsifying Agents

API Stability Enhancers

Rheology Modifiers

Digital Content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

Global Sales Information

Do you need Business Intel? Ask us

US Medicaid Prescriptions

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Finished Drug Prices

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Annual Reports

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Market Place

Do you need sourcing support? Ask us

APIs

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDF DOSSIERS

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

US Patents

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

US Exclusivities

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Health Canada Patents

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Fidaxomicin Manufacturers

A Fidaxomicin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Fidaxomicin, including repackagers and relabelers. The FDA regulates Fidaxomicin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Fidaxomicin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Fidaxomicin manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Fidaxomicin Suppliers

A Fidaxomicin supplier is an individual or a company that provides Fidaxomicin active pharmaceutical ingredient (API) or Fidaxomicin finished formulations upon request. The Fidaxomicin suppliers may include Fidaxomicin API manufacturers, exporters, distributors and traders.

click here to find a list of Fidaxomicin suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Fidaxomicin USDMF

A Fidaxomicin DMF (Drug Master File) is a document detailing the whole manufacturing process of Fidaxomicin active pharmaceutical ingredient (API) in detail. Different forms of Fidaxomicin DMFs exist exist since differing nations have different regulations, such as Fidaxomicin USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Fidaxomicin DMF submitted to regulatory agencies in the US is known as a USDMF. Fidaxomicin USDMF includes data on Fidaxomicin's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Fidaxomicin USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Fidaxomicin suppliers with USDMF on PharmaCompass.

Fidaxomicin WC

A Fidaxomicin written confirmation (Fidaxomicin WC) is an official document issued by a regulatory agency to a Fidaxomicin manufacturer, verifying that the manufacturing facility of a Fidaxomicin active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Fidaxomicin APIs or Fidaxomicin finished pharmaceutical products to another nation, regulatory agencies frequently require a Fidaxomicin WC (written confirmation) as part of the regulatory process.

click here to find a list of Fidaxomicin suppliers with Written Confirmation (WC) on PharmaCompass.

Fidaxomicin NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Fidaxomicin as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Fidaxomicin API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Fidaxomicin as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Fidaxomicin and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Fidaxomicin NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Fidaxomicin suppliers with NDC on PharmaCompass.

Fidaxomicin GMP

Fidaxomicin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Fidaxomicin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Fidaxomicin GMP manufacturer or Fidaxomicin GMP API supplier for your needs.

Fidaxomicin CoA

A Fidaxomicin CoA (Certificate of Analysis) is a formal document that attests to Fidaxomicin's compliance with Fidaxomicin specifications and serves as a tool for batch-level quality control.

Fidaxomicin CoA mostly includes findings from lab analyses of a specific batch. For each Fidaxomicin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Fidaxomicin may be tested according to a variety of international standards, such as European Pharmacopoeia (Fidaxomicin EP), Fidaxomicin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Fidaxomicin USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.

Market Place

Home

Menu

Post Enquiry

Market Place

Search